AstraZeneca has announced that its immunotherapy Tagrisso (osimertinib) has been awarded Breakthrough Therapy Designation by the FDA for the first-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Original Article: AstraZeneca's Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC
NEXT ARTICLE